MIR205HG and prostate adenocarcinoma: Reduction of LEADR/MIR205HG expression in PRAD was confirmed in one of the largest available microarray datasets (GSE21034), where its levels tend to decrease progressively as the tumor acquires a more undifferentiated or metastatic phenotype (Fig. 1c).